rivaroxaban group vs 102 of the vitamin K antagonist group p NS Major bleeding 061 of the rivaroxaban group vs 080 of the placebo group p NS Trial design Participants with ID: 930483
Download Presentation The PPT/PDF document "X- VeRT CV death, stroke/TIA, non-CNS sy..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Slide1
X-
VeRT
CV death, stroke/TIA, non-CNS systemic embolism, or MI: 0.51% of the rivaroxaban group vs. 1.02% of the vitamin K antagonist group (p = NS)Major bleeding: 0.61% of the rivaroxaban group vs. 0.80% of the placebo group (p = NS)
Trial design: Participants with nonvalvular atrial fibrillation scheduled for DC cardioversion were randomized to rivaroxaban 20 mg daily (n = 1,002) vs. vitamin K antagonist with target INR 2-3 (n = 502).
Results
Conclusions
Among participants with nonvalvular atrial fibrillation, the use of rivaroxaban around the time of DC cardioversion is feasibleThis medication was associated with a similar incidence of adverse ischemic and bleeding events
Cappato R, et al. Eur Heart J 2014;Sep 2:[Epub]
(p
= NS)
Rivaroxaban
%
0.51
1.02
Placebo